Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended																		12 Months Ended
Liquidity (Details Narrative) - USD ($) $ in Thousands	Apr. 21, 2020	Jan. 31, 2020	Sep. 30, 2019	Nov. 30, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 20, 2020	Mar. 31, 2020	Nov. 30, 2019	Jul. 31, 2019
Cash and cash equivalents					$ 2,321				$ 6,068														$ 2,321	$ 6,068
Accounts receivable, net					10,338				9,483														10,338	9,483
Total current assets					16,510				17,721														16,510	17,721
Total current liabilities					17,292				8,669														17,292	8,669
Net loss					10,663	$ 7,446	$ 5,304	$ 3,326	4,299	$ 3,126	$ 2,001	$ 3,277	$ 3,400	$ 6,390	$ (2,330)	$ 8,003	$ 2,844	$ 5,296	$ 5,405	$ 7,488	$ 4,614	$ 4,454	26,740	12,703	$ (12,553)	$ 22,003	$ 13,623	$ 16,768
Net cash used in operating activities																							18,957	8,673
Line of credit facility					3,000																		3,000
Public offering generating net proceeds																							$ 200
Sale of common stock																							97,817
Stockholder's equity increased			$ 6,030		(4,479)	$ 6,030	$ 13,346	$ 18,372	$ 15,446	$ 18,799	$ 21,406	$ 22,703	$ 19,484	$ 19,532	$ 7,843	$ (5,979)	$ 2,003	$ 4,826	$ 3,400	$ 8,347	$ 15,183	$ 25,306	$ (4,479)	$ 15,446	$ 22,891	$ (10,111)	$ 10,067	$ 19,427
Silicon Valley Bank [Member]
Line of credit facility				$ 850	$ 3,000																		$ 3,000
Line of credit facility term loan				3 years
Line of credit facility, description				The proceeds of the term loan are expected to be used for laboratory capital expenditures and will be repaid monthly. The balance of the Line of Credit is available for working capital purposes as a revolving line of credit and has a three-year term. The borrowing limit of the revolving line of credit is the lower of 80% of the Company's eligible accounts receivable (as adjusted by SVB) and the aggregate amount of cash collections with respect to accounts receivable during the three prior calendar months.																			The amount that may be borrowed under the Revolving Line is the lower of (i) $3.75 million or (ii) 80% of the Company's eligible accounts receivable (as adjusted by SVB). Revolving Line outstanding amounts incur interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 0.5%. The Company is also required to pay an unused Revolving Line facility fee monthly in arrears in an amount equal to 0.35% per annum of the average unused but available portion of the Revolving Line. The term loan portion of the SVB Loan Agreement has a maturity date of May 2, 2022, and the Revolving Line has a maturity date three years from the effective date, or November 13, 2021
Line of credit, percentage				0.50%
Silicon Valley Bank [Member] \| Prime Rate [Member]
Line of credit, percentage				5.00%																			0.50%
Silicon Valley Bank [Member] \| Maximum [Member]
Line of credit facility																															$ 4,000
Subsequent Event [Member]
Line of credit facility																														$ 350
Stockholder's equity increased		$ 47,000
Description for loans to qualifying businesses value and its term	As of April 20, 2020, the Company's PPP loan has not yet been approved, pending new legislation increasing the pool. The PPP provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. If the Company is successful in obtaining a PPP loan, we intend to use the proceeds for purposes consistent with the PPP and expect to meet the conditions for forgiveness of the loan.
Cash	$ 18,400
Subsequent Event [Member] \| Credit Facility [Member]
Cash																													$ 3,400
Subsequent Event [Member] \| Maximum [Member] \| Credit Facility [Member]
Cash	8,000																												8,000
Subsequent Event [Member] \| Minimum [Member] \| Credit Facility [Member]
Cash	4,000																												4,000
Subsequent Event [Member] \| Preferred Stock [Member]
Public offering generating net proceeds		$ 19,500
Sale of common stock		20,000
Security Purchase and Exchange Agreement [Member]
Line of credit facility																																$ 4,000
Equity Distribution Agreement [Member]
Public offering generating net proceeds			$ 4,800
ATM Agreement [Member]
Public offering generating net proceeds																							$ 8,000
Small Business Administration [Member] \| Subsequent Event [Member]
Loans payable																													3,500
Department of Health and Human Services [Member] \| Subsequent Event [Member]
Loans payable																													650
Proceeds from loans payable	650
Centers for Medicare & Medicaid Services [Member] \| Subsequent Event [Member]
Loans payable																													$ 2,100
Proceeds from loans payable	$ 2,100